Runt-Related Transcription Factor 2 (Runx2) Is Responsible for Galectin-3 Overexpression in Human Thyroid Carcinoma

被引:13
|
作者
Kaptan, Engin [1 ]
Bas, Serap Sancar [1 ]
Sancakli, Aylin [1 ]
Aktas, Hatice Gumushan [2 ]
Bayrak, Bertan Boran [3 ]
Yanardag, Refiye [3 ]
Bolkent, Sehnaz [1 ]
机构
[1] Istanbul Univ, Dept Biol, Fac Sci, TR-34134 Istanbul, Turkey
[2] Harran Univ, Art & Sci Fac, Dept Biol, TR-63300 Sanliurfa, Osmanbey, Turkey
[3] Istanbul Univ, Dept Chem, Fac Engn, TR-34320 Istanbul, Turkey
关键词
THYROID CARCINOMA; Runx2; Galectin-3; MMP-2; MMP-9; PROSTATE-CANCER; DIFFERENTIAL EXPRESSION; PITUITARY-TUMORS; DOWN-REGULATION; BREAST-CANCER; CELL-LINES; MATRIX; PROGRESSION; METASTASIS; APOPTOSIS;
D O I
10.1002/jcb.26043
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Runx2 promotes metastatic ability of cancer cells by directly activating some of the mediators regarding malignancy. Galectin-3 (Gal-3) extensively expressed in normal and transformed cells and it is responsible for many cellular processes. In this study, we aimed to investigate whether there is any relationship between runx2 transcription factor and regulation of galectin-3 expression in different human thyroid carcinoma cell lines. To show effects of runx2 transcription factor on gal-3 expression, we developed runx2 knockdown model in the thyroid carcinoma cell lines; anaplastic 8505C and 8305C and, papillary TPC-1 and follicular FTC-133 by using siRNA transfection. We analyzed the protein expressions and mRNA levels of gal-3 and MMP2/9 in the runx2-silenced cell lines using Western blotting, qPCR, and fluorescent microscopy. Our results showed that mRNA expression levels of gal-3 and MMP2/9 were downregulated in runx2-silenced cell lines. In this investigation, we revealed that regulation of gal-3 expression was strongly correlated with runx2 transcription factor in human thyroid carcinoma. Considering the contribution of human gal-3 in collaboration with MMP2/9 to the malignant characters of many cancers, regulation of their expressions through runx2 seems like one of the key regulatory mechanism for malignant potential of human thyroid carcinoma. Accordingly, runx2 transcription factor inhibitors can be a potential target in order to prevent gal-3 mediated malignancy of human thyroid carcinoma. J. Cell. Biochem. 118: 3911-3919, 2017. (c) 2017 Wiley Periodicals, Inc.
引用
收藏
页码:3911 / 3919
页数:9
相关论文
共 50 条
  • [31] O-GlcNAc Modification of the runt-Related Transcription Factor 2 (Runx2) Links Osteogenesis and Nutrient Metabolism in Bone Marrow Mesenchymal Stem Cells
    Nagel, Alexis K.
    Ball, Lauren E.
    MOLECULAR & CELLULAR PROTEOMICS, 2014, 13 (12) : 3381 - 3395
  • [32] The Cleidocranial Dysplasia-Related R131G Mutation in the Runt-Related Transcription Factor RUNX2 Disrupts Binding to DNA But Not CBF-β
    Han, Min-Su
    Kim, Hyo-Jin
    Wee, Hee-Jun
    Lim, Kyung-Eun
    Park, Na-Rae
    Bae, Suk-Chul
    van Wijnen, Andre J.
    Stein, Janet L.
    Lian, Jane B.
    Stein, Gary S.
    Choi, Je-Yong
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2010, 110 (01) : 97 - 103
  • [33] Loss of Runt-Related Transcription Factor 3 Expression Associated with Human Hepatocellular Carcinoma Progression and Prognosis
    Li, Jianguo
    Jiang, Xiaojie
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (09) : 2285 - 2290
  • [34] Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage
    Ozaki, T.
    Wu, D.
    Sugimoto, H.
    Nagase, H.
    Nakagawara, A.
    CELL DEATH & DISEASE, 2013, 4 : e610 - e610
  • [35] Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage
    T Ozaki
    D Wu
    H Sugimoto
    H Nagase
    A Nakagawara
    Cell Death & Disease, 2013, 4 : e610 - e610
  • [36] Loss of Runt-Related Transcription Factor 3 Causes Development and Progression of Hepatocellular Carcinoma
    Shiraha, Hidenori
    Nishina, Shin-ichi
    Yamamoto, Kazuhide
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2011, 112 (03) : 745 - 749
  • [37] MicroRNA-34c Inversely Couples the Biological Functions of the Runt-related Transcription Factor RUNX2 and the Tumor Suppressor p53 in Osteosarcoma
    van der Deen, Margaretha
    Taipaleenmaeki, Hanna
    Zhang, Ying
    Teplyuk, Nadiya M.
    Gupta, Anurag
    Cinghu, Senthilkumar
    Shogren, Kristen
    Maran, Avudaiappan
    Yaszemski, Michael J.
    Ling, Ling
    Cool, Simon M.
    Leong, David T.
    Dierkes, Christian
    Zustin, Jozef
    Salto-Tellez, Manuel
    Ito, Yoshiaki
    Bae, Suk-Chul
    Zielenska, Maria
    Squire, Jeremy A.
    Lian, Jane B.
    Stein, Janet L.
    Zambetti, Gerard P.
    Jones, Stephen N.
    Galindo, Mario
    Hesse, Eric
    Stein, Gary S.
    van Wijnen, Andre J.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (29) : 21307 - 21319
  • [38] Runt-related Transcription Factor 1 (RUNX1) is a mediator of acute kidney injury
    Villar Gomez, Natalia
    Fontecha-Barriuso, Miguel
    Guerrero Mauvecin, Juan
    Ortiz, Alberto
    Belen Sanz, Ana
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1800 - I1800
  • [39] Association of runt-related transcription factor 3 (Runx3) and organic cation transporters 1 and 2 (Octn1/2) with inflammatory bowel disease
    Weersma, Rinse K.
    Zhou, Lit
    Nolte, Ilja M.
    Van der steege, Gerrit
    Van dullemen, Hendrik M.
    Oosterom, Elvira
    Faber, Klaas N.
    Peppelenbosch, Maikel P.
    Kleibeuker, Jan H.
    Dijkstra, Gerard
    GASTROENTEROLOGY, 2007, 132 (04) : A152 - A152
  • [40] Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma
    Tanaka, Shigetomi
    Shiraha, Hidenori
    Nakanishi, Yutaka
    Nishina, Shin-Ichi
    Matsubara, Minoru
    Horiguchi, Shigeru
    Takaoka, Nobuyuki
    Iwamuro, Masaya
    Kataoka, Junro
    Kuwaki, Kenji
    Hagihara, Hiroaki
    Toshimori, Junichi
    Ohnishi, Hideki
    Takaki, Akinobu
    Nakamura, Shinichiro
    Nouso, Kazuhiro
    Yagi, Takahito
    Yamamoto, Kazuhide
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (11) : 2537 - 2546